Clinuvel Pharmaceuticals (ASX:CUV) strategic update fails to boost investor appetite

Company News

by Michael Luu

Genetic and vascular disorder treatment company Clinuvel Pharmaceuticals (ASX:CUV) released a new strategic update on Monday.

The firm plans to expand its research capabilities for skin cancer treatments and damage remediation. The establishment of a new manufacturing division is on the company’s strategic agenda to advance new treatment formulas.

The strategic update has done little to boost investor appetite, as shares in Clinuvel Pharmaceuticals are trading 2.42 per cent lower at $29.39 .

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.